Patents Assigned to Inserm
-
Patent number: 11479817Abstract: The present invention relates to a method for discriminating an operationally tolerant (TOL) subject from a non-operationally tolerant (STA) subject, comprising the following steps: i) establishing a composite score of tolerance (cSoT) with the expression levels of six genes in a biological sample obtained from said subject and two clinical parameters; wherein said six genes are ID3, AKR1C3, CD40, CTLA4, TCL1A and MZB1, and wherein said cSoT is established by the following formula: cSoT = ? i n ? = ? i × Exprs + ? test ? ? time × age test ? ? time + ? trans ? ? time × age trans ? ? time + intercept - scaling ? ? coefficient ii) comparing this cSoT with a predetermined reference value; and iii) concluding that the subject is TOL when the cSoT is higher than the predetermined reference value or concluding that the subject is STA when the cSoT is lower than the predetermined reference value.Type: GrantFiled: July 21, 2017Date of Patent: October 25, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Centre Hospitalier Universitaire de Nantes, Centre National de la Recherche ScientifiqueInventors: Richard Danger, Sophie Brouard, Magali Giral, Gérard Ramstein
-
Patent number: 11478486Abstract: The invention concerns a pharmaceutical combination of an inhibitor of the androgen receptor signaling pathway and of a p38 inhibitor for use in the treatment of prostate cancer in individuals wherein the prostate tumor cells express the AR-V7 variant androgen receptor protein or for preventing the occurrence of resistance in patients suffering from prostate cancer treated by an inhibitor of the androgen receptor signaling pathway. The invention further concerns a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient.Type: GrantFiled: November 14, 2018Date of Patent: October 25, 2022Assignees: INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIERInventors: Céline Gongora, Diego Tosi
-
Publication number: 20220333177Abstract: The present invention relates to a digital method for detecting and/or quantifying at least one target biomolecules in a sample, said biomolecules being selected from DNA, RNA, and proteins based on isothermal amplification. The present invention further relates to different applications of the digital method and to a kit.Type: ApplicationFiled: May 27, 2020Publication date: October 20, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, PARIS SCIENCES ET LETTRES, UNIVERSITE DE PARISInventors: Yannick RONDELEZ, Guillaume GINES, Roberta LIMA DE CASTRO MENEZES, Valérie TALY
-
Patent number: 11473145Abstract: The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).Type: GrantFiled: July 26, 2018Date of Patent: October 18, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), FOUNDATION IMAGING, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE PARISInventors: Pascale De Lonlay-Debeney, Peter Van Endert, Marine Madrange, Yamina Hamel, François-Xavier Mauvais
-
Patent number: 11471558Abstract: The present invention concerns a polyelectrolyte coating comprising at least one polycationic layer consisting of at least one polycation consisting of n repetitive units having the formula (1) and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit.Type: GrantFiled: May 2, 2017Date of Patent: October 18, 2022Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE STRASBOURG, PROTIP MEDICALInventors: Philippe Lavalle, Pierre Schaaf, Nihal Engin Vrana, Angela Mutschler
-
Patent number: 11471538Abstract: The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the molecular mechanisms driving these resistances are not completely understood. The inventors show that expression of 10 SLITRK6 (SLIT and NTRK-like family, member 6) is induced by a MAPK inhibitor (e.g. Vemurafenib) and the inhibition of its induction in presence of the MAPK inhibitor induces synthetic lethality. Thus, the only inhibition of SLITRK6 by an inhibitor of activity or expression should potentiate the antitumor effect of the MAPK inhibitors and avoid the emergence of a resistance to those compounds. Furthermore the specific expression of 15 SLITRK6 also paves the way of strategies based on depletion of the residual cancer cells by targeting them with anti-SLITRK6 antibodies capable of mediating ADCC or antibody-drug conjugates binding to SLITRK6.Type: GrantFiled: February 9, 2018Date of Patent: October 18, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTéET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Gilles Favre, Magdalena Pohorecka
-
Patent number: 11472844Abstract: The invention relates to a peptidomimetic comprising or consisting of a D amino-acid sequence having at least 75% identity with SEQ ID NO: 1 or SEQ ID NO: 2, or variants or fragments thereof, in particular a peptidomimetic having the capability to interact at least with: neutrophils and/or neutrophil granules, and/or lactoferrin, and/or globet-cells and/or Muc2 proteins, and/or mucus and/or airway sputum. The peptidomimetic may have the capacity to adopt a multimeric, especially a trimeric, organization, and can be labelled, or associated with a reporter or a carrier entity, or associated with an active molecule. The invention also relates to a Solid-Phase Synthesis method for synthesizing a peptidomimetic of the invention, compositions comprising the same and use of the peptidomimetics as a medicamentor an inflammation marker or a neutrophilic inflammation marker.Type: GrantFiled: December 11, 2018Date of Patent: October 18, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEURInventors: Benoit Sebastien Marteyn, Yves-Marie Coic, Francoise Baleux
-
Patent number: 11464458Abstract: The invention relates to a non-invasive system for determining the maturation of a baby, which comprises a module for sampling a cardiac or electroencephalographic signal from a baby and advantageously performs a conversion of a plurality of temporal samples derived from the cardiac signal or from the electroencephalic signal into a visibility graph, then a determination of at least one index on the basis of this visibility graph, a comparison of at least one determined index with one or more statistical indices representative of the maturation of a plurality of babies and a visual representation of a distance between at least one determined index and the statistical indices.Type: GrantFiled: September 5, 2018Date of Patent: October 11, 2022Assignees: UNIVERSITÉ DE RENNES 1, CHU DE RENNES, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)Inventors: Guy Carrault, Nadine Khodor, Patrick Pladys, Mathieu Kuchenbuch
-
Patent number: 11467160Abstract: The present invention relates to method of therapy selection for patient suffering from glioblastoma. Using in vitro and in vivo approaches, the inventors demonstrated the critical role of CD90 in GBM migration/invasion. They showed that CD90 signaling though SRC, FAK and RhoA promotes cell migration and importantly, that high CD90 expression impacts on the cell response to the SRC inhibitor dasatinib. In particular, the present invention relates to a method for predicting whether a subject will be eligible to a treatment with a drug selected from the group consisting of SRC inhibitor, FAK inhibitor or RhoA inhibitor by determining the expression level of CD90 in a sample obtained from the subject.Type: GrantFiled: May 9, 2018Date of Patent: October 11, 2022Assignees: INSERM (INSTITUT NAITONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE RENNES I, CENTRE EUGENE MARQUIS, ENIOS APPLICATIONS PRIVATE LIMITED COMPANYInventors: Eric Chevet, Tony Avril, Aristotelis Chatziioannou
-
Patent number: 11469433Abstract: Thermo-electric generator which is intended to be immersed in a fluid which contains at least one chemical species, comprising two electrodes each having a first end and a second end, the first ends being connected to each other, the generator being configured to generate an electrical voltage between the two ends when a temperature difference is imposed between each first end and the corresponding second end, the temperature difference being such that one end, referred to as the “hot end”, of each electrode has a temperature which is strictly greater than the temperature of the other end. The hot end of at least one electrode comprises a micro-organism or an enzyme which is capable of causing at least one exothermic reaction involving the chemical species.Type: GrantFiled: May 23, 2019Date of Patent: October 11, 2022Assignees: UNIVERSITE GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER RÉGIONAL DE GRENOBLEInventors: Abdelkader Zebda, Philippe Cinquin, Jean-Pierre Alcaraz, Donald Martin, Aziz Bakri, Nawel Khalef
-
Patent number: 11464407Abstract: A method for generating an indicator or biomarker of colour perception in a mammalian subject, where the method may include submitting the mammalian subject to a multicoloured dynamic stimulus comprising displaying, on a display device. The method may include controlling a change over time of at least one of the two colours of the multicolour pattern when displaying the dynamic multicolour stimulus, to vary the displayed luminance of this colour (usually several times). The method may include acquiring, by using an image acquisition device, an oscillatory response of a pupil of the mammalian subject. The method may include generating, from the acquired response, a signal representative of the power of the pupil's oscillatory response as a function of the change over time of at least one of the two colours when displaying the dynamic multicoloured stimulus.Type: GrantFiled: March 29, 2018Date of Patent: October 11, 2022Assignees: INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE (ICM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CRNS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP), SORBONNE UNIVERSITEInventors: Pierre Pouget, Alexis Genin
-
Patent number: 11460467Abstract: The present invention relates to an in vitro method for diagnosing lupus in a subject, said method comprising the step of detecting in a biological sample obtained from the subject the autoantibody recognizing the protein biomarker THEX1. More, the invention relates to kits and array useful for carrying out diagnosis methods according to the present invention.Type: GrantFiled: February 7, 2019Date of Patent: October 4, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, GFRS (Groupe Francophone de Recherche sur la Sclerodermie Systemique)Inventors: Nathalie Lambert, Fanny Arnoux, Doua Azzouz
-
Patent number: 11458194Abstract: The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.Type: GrantFiled: May 24, 2017Date of Patent: October 4, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITE PARIS-SACLAY, UNIVERSITE PARIS CITEInventors: Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli
-
Patent number: 11458118Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.Type: GrantFiled: April 20, 2018Date of Patent: October 4, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BRETAGNE OCCIDENTALE, ETABLISSEMENT FRANÇAIS DU SANG (EFS), CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BRESTInventors: Pascal Trouve, Claude Ferec, Mathieu Kerbiriou, Florentin Huguet
-
Patent number: 11448656Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.Type: GrantFiled: July 17, 2018Date of Patent: September 20, 2022Assignees: CNRS, CONICET, INSTITUT JEAN PAOLI & IRENE CALMETES, UNIVERSITE D' AIX-MARSEILLE, INSERMInventors: Juan Iovanna, Virginia Pasquinelli, Maria Madgalena Gherardi, Hector Eduardo Chuluyan, Ana Inès Rovetta, Delfina Pena, Véronica Edith Garcia
-
Patent number: 11446372Abstract: A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.Type: GrantFiled: April 14, 2020Date of Patent: September 20, 2022Assignees: Institut Pasteur de Lille, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)Inventors: Anne-Sophie Debrie, Dominique Raze, Camille Locht
-
Patent number: 11440906Abstract: The present disclosure relates to biguanide derivatives of formula (I) and their rearrangement products. The present disclosure also relates to the use of these compounds in a method for treating cancer, in particular melanoma.Type: GrantFiled: December 21, 2018Date of Patent: September 13, 2022Assignees: Centre National de la Recherche Scientifique, INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'AzurInventors: Rachid Benhida, Stephane Rocchi, Cyril Ronco, Emile Jaune, Oleksandr Grytsai, Nedra Tekaya
-
Publication number: 20220280498Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.Type: ApplicationFiled: May 26, 2022Publication date: September 8, 2022Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SUD, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUEInventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
-
Publication number: 20220275372Abstract: The present invention relates to conjugates formed from a cell-penetrating peptide carrier linked to a therapeutic molecule, wherein the peptide carrier is defined by specific domains and the therapeutic molecule is a nucleic acid formed of trinucleotide repeats. The present invention further relates to the use of such a conjugate in methods of treatment or as a medicament, especially in the treatment of trinucleotide repeat disorders such as myotonic dystrophy (DM1).Type: ApplicationFiled: August 7, 2020Publication date: September 1, 2022Applicants: OXFORD UNIVERSITY INNOVATION LIMITED, UNITED KINGDOM RESEARCH AND INNOVATION, ASSOCIATION INSTITUT DE MYOLOGIE, INSERM (INSTITUT NATONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITEInventors: Matthew Wood, Miguel Varela, Ashling Holland, Richard Raz, Denis Furling, Arnaud Klein, Michael Gait
-
Publication number: 20220275420Abstract: A biomass-based enzymatic biocathode based on glucose, monosaccharide, ketone or aldehyde includes a collector conductor support, conductive particles disposed on and bound to said collector conductor support, and an aldose reductase disposed on said conductive particles, being bound thereto by adsorption and accessible at the surface of the monosaccharide, ketone or aldehyde reagent that is to be reduced when the biocathode is operational.Type: ApplicationFiled: July 27, 2020Publication date: September 1, 2022Applicants: UNIVERSITÉ GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE - INSERM, GRENOBLE INP (INSTITUT NATIONAL POLYTECHNIQUE), CNRS - CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Abdelkader ZEBDA, Philippe CINQUIN, Donald MARTIN, Thomas SORANZO